Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Michael E. DeBakey: The pioneer of arterial bypass surgery and artificial heart and ventricular-assist devices passed away July 11 at the age of 99 and was laid to rest in Houston July 16. Michael E. DeBakey, M.D., who was chancellor emeritus at Baylor College of Medicine, is credited as the first to recognize that arteriosclerosis typically causes discrete, localized damage to the artery that can be treated surgically with excision and grafting. In 1952, he was the first in the U.S. to successfully perform such a procedure to treat an aortic aneurysm. The following year, he performed the first carotid endarterectomy. DeBakey was also the first to use grafts made of synthetic Dacron material, still used today both for open-heart and endovascular stent-graft aneurysm procedures. In the 1960s, he researched artificial hearts and performed the first successful human implantation of a left ventricular assist device. The DeBakey LVAD, developed by DeBakey in collaboration with the National Aeronautics and Space Administration, is in a bridge-to-transplant FDA clinical trial sponsored by Houston-based MicroMed, and a pediatric version is marketed in the United States under a humanitarian device exemption

You may also be interested in...



From Trains To Treatments: New GE Healthcare CEO Settles In

While it seems like a big change, John Dineen suggests his recent move from chief exec of General Electric's locomotive and drilling equipment business to the top slot at the firm's healthcare unit is a natural transition

From Trains To Treatments: New GE Healthcare CEO Settles In

While it seems like a big change, John Dineen suggests his recent move from chief exec of General Electric's locomotive and drilling equipment business to the top slot at the firm's healthcare unit is a natural transition

SEISMIC Shows Safety Of Bioheart’s Myoblast Therapy For Post-MI Patients

Investigators are encouraged by results of the unblinded SEISMIC safety trial of Bioheart's MyoCell autologous stem-cell therapy for myocardial infarction, but the benefits of the therapy must still be confirmed in a blinded study

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel